The estimated Net Worth of William Rose is at least $4.14 Millón dollars as of 15 July 2005. Mr. Rose owns over 20,666 units of Reata Pharmaceuticals Inc stock worth over $3,561,992 and over the last 21 years he sold RETA stock worth over $0. In addition, he makes $574,629 as Independent Director at Reata Pharmaceuticals Inc.
Sign up
Mr. Rose RETA stock SEC Form 4 insiders trading
William has made over 2 trades of the Reata Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 20,666 units of RETA stock worth $158,715 on 15 July 2005.
The largest trade he's ever made was exercising 20,666 units of Reata Pharmaceuticals Inc stock on 15 July 2005 worth over $158,715. On average, William trades about 1,307 units every 1 days since 2003. As of 15 July 2005 he still owns at least 20,666 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr. Rose stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Rose biography
William E. Rose serves as Independent Director of the Company. Prior to Montrose, Mr. Rose was associated with HBK Capital Management from 1991 until 2012, serving in various capacities, including Co-Chief Investment Officer. He currently serves on the Board of Greenhill School and is also a member of the Investment Committee for the Dallas Museum of Art. Mr. Rose received a B.A. in Political Science from Duke University in 1989. Our Board believes that Mr. Rose is qualified to serve on our Board due to his extensive experience investing, his experience with venture capital investments and his board service for other enterprises.
What is the salary of William Rose?
As the Independent Director of Reata Pharmaceuticals Inc, the total compensation of William Rose at Reata Pharmaceuticals Inc is $574,629. There are 12 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.
How old is William Rose?
William Rose is 51, he's been the Independent Director of Reata Pharmaceuticals Inc since 2016. There are 7 older and 8 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
What's William Rose's mailing address?
William's mailing address filed with the SEC is 4215 WEST LOVERS LANE, SUITE 200, , DALLAS, TX, 75209.
Insiders trading at Reata Pharmaceuticals Inc
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy y Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
What does Reata Pharmaceuticals Inc do?
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
What does Reata Pharmaceuticals Inc's logo look like?
Complete history of Mr. Rose stock trades at Reata Pharmaceuticals Inc y Impac Mortgage
Reata Pharmaceuticals Inc executives and stock owners
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Manmeet Soni,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
J. Warren Huff,
Chairman of the Board, President, Chief Executive Officer -
Colin Meyer,
Executive Vice President, Chief Research and Development Officer -
Michael Wortley,
Executive Vice President, Chief Legal Officer -
Dawn Bir,
Executive Vice President, Chief Commercial Officer -
Manmeet Singh Soni,
COO, CFO & Pres -
J. Warren Huff,
Chairman & CEO -
Dr. Colin J. Meyer M.D.,
Exec. VP & Chief Innovation Officer -
Michael D. Wortley,
Exec. VP & Chief Legal Officer -
Dawn Carter Bir,
Exec. VP & Chief Commercial Officer -
Jack Nielsen,
Independent Director -
William McClellan,
Independent Director -
William Rose,
Independent Director -
R. Kent McGaughy,
Independent Director -
Vineet Jindal,
Vice President, Corporate Communications and Strategy -
Martin Edwards,
Independent Director -
Seemi Khan,
Chief Medical Officer -
Andrea Loewen,
Vice President - Global Regulatory Affairs -
Kevin Johnston,
Chief Technical Officer, Vice President -
Steve Harman,
VP & Chief HR Officer -
Dakota Gallivan,
VP & Chief Healthcare Compliance Officer -
Dr. W. Christian Wigley Ph.D.,
Sr. VP & Chief Scientific Officer -
Bhaskar Anand,
VP & Chief Accounting Officer -
William Puffin Partners, L....,
-
Dennis K. Stone,
Director -
Elaine Castellanos,
VP, Chief Accounting Officer -
Holdings A/S Novo,
10% owner -
James Edward Bass,
Director -
James W Jr Traweek,
-
Inc Cpmg,
-
Inc. Abb Vie,
10% owner -
Keith Wayne Ward,
See Remarks -
William Rose Evelyn P.Edwar...,
-
William Puffin Partners, L....,
-
Antal Rohit Cpmg Inc Desai,
-
William Montrose Investment...,
-
William Charles Henry Rose ...,
-
William Puffin Partners, L....,
-
William Estate Of Edward W....,
-
Jason Douglas Wilson,
Executive VP of Operations -
Pharma Llcstapleton Craig R...,
-
Christy J. Oliger,
Director -
Shamim Ruff,
Director -
Bhaskar Anand,
SVP, Chief Accounting Officer -
Steven Ryder,
Director -
Samina Khan,
SVP, Chief Medical Officer -
Rajiv Patni,
EVP, Chief R&D Officer